Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Exact Sciences Corporation.
Advances In™: Testing and Treatment of Metastatic CRPC with PARP Inhibitors
Release Date: November 30, 2021
Expiration Date: November 30, 2022
Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of metastatic castration-resistant prostate cancer (mCRPC) with PARP inhibitors with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of biomarkers tests and testing guidelines, current and emerging PARP inhibitors for the management of CRPC, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Exact Sciences Corporation.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline molecular and biomarker testing guidelines in the context of guiding care in metastatic castration-resistant prostate cancer (mCRPC) settings.
- Evaluate clinical trial evidence from investigations that have evaluated PARP inhibitors for the treatment of mCRPC.
- Formulate strategies to monitor for and mitigate the impact of adverse events associated with PARP inhibitor approaches utilized among men with prostate cancer.
- Integrate PARP inhibitor therapy into personalized care plans for the treatment of mCRPC.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty
Head, Section of GU Oncology
Associate Professor of Medicine
Division of Oncology
USC Norris Comprehensive Cancer Center
Keck School of Medicine of USC
Medical Director
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Disclosures: Grant/Research Support: Merck, Pfizer, Genentech; Consultant: Astellas, Merck, Bayer, Roche/Genentech, Novartis, BMS
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
